State Attorneys General to FDA: What Were You Thinking When You Approved Powerful New Painkiller?

<a href="http://en.wikipedia.org/wiki/File:Ritalin-SR-20mg-1000x1000.jpg">Wikimedia</a>

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.


Last month, Mother Jones reported that the Food and Drug Administration had approved a powerful new painkiller called Zohydro over the objections of its advisory board, which voted 11-2 against approving the drug. Now Attorneys General from 28 states (and the US territory of Guam) have asked the FDA to reconsider its approval of Zohydro. In a letter to the agency, the AGs raise many of the same concerns that the advisory panel did, noting that the drug lacks adequate safeguards to prevent it from being abused and could exacerbate America’s epidemic of painkiller deaths. Here’s an excerpt from the AGs letter, which was dated December 10:

State Attorneys General do not want a repeat of the recent past when potent prescription painkilling drugs entered the market without abuse-deterrent qualities and without clear guidance on how they were to be prescribed. This created an environment whereby our nation witnessed a vicious cycle of overzealous pharmaceutical sales, doctors over-prescribing the narcotics, and patients tampering with these drugs, ultimately resulting in a nationwide prescription drug epidemic claiming thousands of lives.

Zohydro, which is made by a company called Zogenix, is five to ten times stronger than Vicodin, making it very similar in potency to OxyContin, a widely abused prescription drug that has contributed to the tens of thousands of painkiller-related deaths in the United States. OxyContin, however, now includes a gel that prevents the drug from being crushed and snorted. Zohydro was approved without that measure. Zogenix has entered into a $750,000 agreement with a Montreal-based company, Altus Formulation Inc, to help make the drug abuse-deterrent, but it’s unclear whether the formula will be ready by the time Zohydro hits the market in a few months.

The Attorneys General don’t think that’s sufficient. “We hope that the FDA either reconsiders its approval of Zohydro ER, or sets a rigorous timeline for Zohydro ER to be reformulated to be abuse-deterrent while working with other federal agencies to impose restrictions on how Zohydro ER can be marketed and prescribed,” they wrote in their letter.

FACT:

Mother Jones was founded as a nonprofit in 1976 because we knew corporations and the wealthy wouldn't fund the type of hard-hitting journalism we set out to do.

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation today so we can keep on doing the type of journalism 2020 demands.

payment methods

FACT:

Mother Jones was founded as a nonprofit in 1976 because we knew corporations and the wealthy wouldn't fund the type of hard-hitting journalism we set out to do.

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation today so we can keep on doing the type of journalism 2020 demands.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate